Vistagen Therapeutics (VTGN) Assets Average (2012 - 2026)
Vistagen Therapeutics (VTGN) posted Assets Average of $56.8 million for Q1 2026, down 22.17% sequentially from $73.0 million in Q4 2025, and down 35.68% YoY from $88.3 million in Q1 2025.
Vistagen Therapeutics (VTGN) Assets Average (2012 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Assets Average for 12 years, with the latest figure at $56.8 million in Q1 2026.
- Quarterly Assets Average fell 35.68% year-over-year to $56.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.8 million (down 35.68% YoY) and the FY2026 annual result came in at $66.5 million, down 36.1% from the prior year.
- Assets Average declined to $56.8 million in Q1 2026 per VTGN's latest filing, from $73.0 million in the prior quarter.
- Over five years, Assets Average peaked at $127.4 million in Q1 2024 and troughed at $18.1 million in Q2 2023.
- A 5-year average of $71.4 million and a median of $74.9 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average tumbled 72.92% in 2023, then surged 556.68% in 2024.
- Over 5 years, Assets Average stood at $35.2 million in 2022, then jumped by 146.08% to $86.6 million in 2023, then increased by 12.43% to $97.4 million in 2024, then fell by 25.06% to $73.0 million in 2025, then retreated by 22.17% to $56.8 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $56.8 million, $73.0 million, and $74.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | 42.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.81 Mn |
| Dec 31, 2025 | 72.99 Mn |
| Sep 30, 2025 | 74.93 Mn |
| Jun 30, 2025 | 76.63 Mn |
| Mar 31, 2025 | 88.32 Mn |
| Dec 31, 2024 | 97.40 Mn |
| Sep 30, 2024 | 108.02 Mn |
| Jun 30, 2024 | 118.60 Mn |
| Mar 31, 2024 | 127.36 Mn |
| Dec 31, 2023 | 86.63 Mn |
| Sep 30, 2023 | 28.61 Mn |
| Jun 30, 2023 | 18.06 Mn |
| Mar 31, 2023 | 25.40 Mn |
| Dec 31, 2022 | 35.21 Mn |
| Sep 30, 2022 | 49.71 Mn |
| Jun 30, 2022 | 66.68 Mn |
| Mar 31, 2022 | 82.59 Mn |
| Dec 31, 2021 | 95.52 Mn |
| Sep 30, 2021 | 102.20 Mn |
| Jun 30, 2021 | 106.09 Mn |